FDA Says Lux's Uveitis Treatment Luveniq Needs Another Clinical Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
In a "complete response" letter following the last-minute cancellation of an advisory committee review in June, FDA asks the biotech to do an additional confirmatory study.